These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23434388)

  • 1. Herd immunity effect of the HPV vaccination program in Australia under different assumptions regarding natural immunity against re-infection.
    Korostil IA; Peters GW; Law MG; Regan DG
    Vaccine; 2013 Apr; 31(15):1931-6. PubMed ID: 23434388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Papillomavirus (HPV) Vaccine Effectiveness and Potential Herd Immunity for Reducing Oncogenic Oropharyngeal HPV-16 Prevalence in the United Kingdom: A Cross-sectional Study.
    Mehanna H; Bryant TS; Babrah J; Louie K; Bryant JL; Spruce RJ; Batis N; Olaleye O; Jones J; Struijk L; Molijn A; Vorsters A; Rosillon D; Taylor S; D'Souza G
    Clin Infect Dis; 2019 Sep; 69(8):1296-1302. PubMed ID: 30590469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination.
    Matthijsse SM; Hontelez JAC; Naber SK; van Rosmalen J; Rozemeijer K; Penning C; Bakker R; van Ballegooijen M; de Kok IMCM; de Vlas SJ
    Vaccine; 2015 Oct; 33(41):5357-5364. PubMed ID: 26348405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.
    Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Liu B; Bateson D; McNamee K; Garefalakis M; Phillips S; Cummins E; Malloy M; Garland SM
    Lancet Infect Dis; 2014 Oct; 14(10):958-66. PubMed ID: 25107680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
    Regan DG; Philp DJ; Hocking JS; Law MG
    Sex Health; 2007 Sep; 4(3):147-63. PubMed ID: 17931528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models.
    Brisson M; Bénard É; Drolet M; Bogaards JA; Baussano I; Vänskä S; Jit M; Boily MC; Smith MA; Berkhof J; Canfell K; Chesson HW; Burger EA; Choi YH; De Blasio BF; De Vlas SJ; Guzzetta G; Hontelez JAC; Horn J; Jepsen MR; Kim JJ; Lazzarato F; Matthijsse SM; Mikolajczyk R; Pavelyev A; Pillsbury M; Shafer LA; Tully SP; Turner HC; Usher C; Walsh C
    Lancet Public Health; 2016 Nov; 1(1):e8-e17. PubMed ID: 29253379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus vaccination and the role of herd effects in future cancer control planning: a review.
    Malagón T; Laurie C; Franco EL
    Expert Rev Vaccines; 2018 May; 17(5):395-409. PubMed ID: 29715059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population-Level Herd Protection of Males From a Female Human Papillomavirus Vaccination Program: Evidence from Australian Serosurveillance.
    Pillsbury AJ; Quinn HE; Evans TD; McIntyre PB; Brotherton JML
    Clin Infect Dis; 2017 Sep; 65(5):827-832. PubMed ID: 29017279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
    Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
    Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling multi-site transmission of the human papillomavirus and its impact on vaccination effectiveness.
    Lemieux-Mellouki P; Drolet M; Jit M; Gingras G; Brisson M
    Epidemics; 2017 Dec; 21():80-87. PubMed ID: 28916210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013.
    Cameron RL; Kavanagh K; Pan J; Love J; Cuschieri K; Robertson C; Ahmed S; Palmer T; Pollock KG
    Emerg Infect Dis; 2016 Jan; 22(1):56-64. PubMed ID: 26692336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender-neutrality, herd effect and resilient immune response for sustainable impact of HPV vaccination.
    Lehtinen M; Apter D
    Curr Opin Obstet Gynecol; 2015 Oct; 27(5):326-32. PubMed ID: 26308204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia.
    Smith MA; Lew JB; Walker RJ; Brotherton JM; Nickson C; Canfell K
    Vaccine; 2011 Nov; 29(48):9112-22. PubMed ID: 21419773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis.
    Van de Velde N; Brisson M; Boily MC
    Vaccine; 2010 Jul; 28(33):5473-84. PubMed ID: 20573580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
    Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
    Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence.
    Bogaards JA; Coupé VM; Xiridou M; Meijer CJ; Wallinga J; Berkhof J
    Epidemiology; 2011 Jul; 22(4):505-15. PubMed ID: 21540743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine-an interrupted time series analysis from 2005 to 2010 using health insurance data.
    Thöne K; Horn J; Mikolajczyk R
    BMC Infect Dis; 2017 Aug; 17(1):564. PubMed ID: 28806926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of human papillomavirus in teenage heterosexual males following the implementation of female and male school-based vaccination in Australia: 2014-2017.
    Chow EPF; Tabrizi SN; Fairley CK; Wigan R; Machalek DA; Regan DG; Hocking JS; Garland SM; Cornall AM; Atchison S; Bradshaw CS; McNulty A; Owen L; Marshall L; Russell DB; Kaldor JM; Chen MY
    Vaccine; 2019 Oct; 37(46):6907-6914. PubMed ID: 31562001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling patterns of clearance of HPV-16 infection and vaccination efficacy.
    Baussano I; Garnett G; Segnan N; Ronco G; Vineis P
    Vaccine; 2011 Feb; 29(6):1270-7. PubMed ID: 21145375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
    Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK
    Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.